KERENDIA
PeakNDAORALTABLETPriority Review
Approved
Jul 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
8
Data completeness
5/8 — Partial
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KERENDIA (finerenone) is a nonsteroidal mineralocorticoid receptor antagonist (MRA) administered orally as a tablet for chronic kidney disease in patients with type 2 diabetes. It works by blocking mineralocorticoid receptors to reduce renal and cardiovascular fibrosis and inflammation. The drug represents a new mechanistic approach to kidney protection beyond standard renin-angiotensin-aldosterone system inhibitors.
$0.27BPart D
Peak8.7 years to LOEProduct is in peak commercial phase with $270M in Part D spending and strong uptake, indicating active brand team growth and commercial expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (8)
A Study to Learn More About How Well Finerenone Works in Real-world in People With Type 2 Diabetes and Chronic Kidney Disease in Primary Care (IMSS= Instituto Mexicano Del Seguro Social)
Started Oct 2026
800 enrolled
Type 2 DiabetesChronic Kidney Disease (CKD) Stages G2 to G3b
Role of Finerenone in African American Veterans With Diabetic Kidney Disease
Started Oct 2026
30 enrolled
Diabetic Kidney Disease
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice
Started Sep 2025
1,200 enrolled
Chronic Kidney DiseaseType 2 Diabetes Mellitus
An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population.
Started Jul 2025
6,537 enrolled
Chronic Kidney DiseaseType 2 Diabetes Mellitus
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States
Started Oct 2024
238,038 enrolled
Chronic Kidney DiseaseType 2 Diabetes Mellitus
Worked on KERENDIA at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.